Long-Acting Therapies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria

The Unitaid-funded LONGEVITY project aims to develop long-acting formulations of an existing prophylaxis for malaria prevention, therapy for latent TB infection, and a curative therapy for hepatitis C virus (HCV) in high volumes and at lower prices for low- and middle-income countries, as these diseases disproportionately affect children, poor and marginalized communities, people who use drugs, and people living with HIV. Long-acting therapies are formulations that allow for the slow release of medication into the bloodstream over prolonged periods of time.

As a partner in the LONGEVITY project, Treatment Action Group (TAG) released a trials tracker, an update of the 2023 Long-Acting Technologies Trials Tracker for Hepatitis C, Opioid Use and Overdose Prevention Therapy, and Malaria, providing a compilation of ongoing and recently completed clinical trials on long-acting therapies for these uses in the research and development (R&D) pipeline.

While the LONGEVITY candidate treatments are still being evaluated preclinically, the trials tracker monitors ongoing and recently completed studies on long-acting therapies for HCV, malaria, and opioid use and overdose prevention. The trials in this tracker are listed on the United States clinicaltrials.gov website, the European Union clinicaltrialsregister.eu registry website, the WHO International Clinical Trials Registry Platform website, and peer-reviewed literature.

The clinical trials were compiled between February 15 and May 30, 2024, and will be updated on an annual basis. Please send updates, corrections, or suggestions to Joelle Dountio Ofimboudem at jdountio@treatmentactiongroup.org.